| Literature DB >> 32572690 |
Juan Fang1, Zhicheng Pan1, Dongfei Wang1, Jialan Lv1, Yang Dong1, Rui Xu1, Yunpeng Jin2, Jianpeng Sheng3, Xiang Yin1, Xudong Xie1, Xingxiang Wang1, Xiaogang Guo4.
Abstract
Multiple ANRIL transcriptional isoforms, such as lncANRIL and circANRIL have been identified. We sought to explore their diagnostic value in patients with coronary artery disease (CAD). First, we selected six target ANRIL isoforms and measured their expression in CAD patients and controls in the peripheral blood. Their diagnostic values were evaluated. circANRIL(exon14-4) was identified as the best potential biomarker. Afterwards, we validated its diagnostic value and evaluated its prognostic value in a larger clinical cohort. Among six tested ANRILs, lncANRIL(exon1) and lncANRIL(exon4-6) in the CAD patients were significantly increased, while circANRIL(exon14-4) was downregulated. circANRIL(exon14-4) had the highest diagnostic value among the three isoforms. The combination of circANRIL(exon14-4) and other factors resulted in a more accurate differentiation of CAD patients. Moreover, lower expression of circANRIL(exon14-4) was associated with higher incidence of MACE. circANRIL(exon14-4) is closely associated with CAD risk and severity, which provides a promising circulating biomarker for CAD diagnosis and prognosis.Entities:
Keywords: Biomarker; Coronary artery disease; circANRIL; lncANRIL
Mesh：
Substances：
Year: 2020 PMID： 32572690 DOI： 10.1007/s12265-020-10053-0
Source DB: PubMed Journal: J Cardiovasc Transl Res ISSN： 1937-5387 Impact factor: 4.132